EMAS Pharma has rebranded as Evestia Clinical as it sets its sights on rapid growth as a provider of clinical research in oncology and rare diseases globally.

Evestia Clinical is backed by Kester Capital and headed by Richard Barfield (Chairman), Lewis Cameron (CEO), Roy Ovel (CCO), and Carl Hvass (CFO). The name Evestia is inspired by the company’s mission to pioneer transformational advancements in clinical research. It represents a commitment to making a lasting imprint in the industry by driving meaningful progress in oncology and rare disease trials and strengthening partnerships with biotech companies.

Evestia Clinical’s mission is “to empower biotech innovators by providing expert-driven, agile, and personalized clinical research solutions—accelerating the development of life-changing therapies with confidence and care.”

“We are committed to providing our clients with the most effective and adaptive clinical trial solutions,” said Lewis Cameron, CEO. “This transformation aligns with our long-term vision of being the preferred CRO partner for biotech companies focused on complex, high-impact research areas.”